action of glp 1 agonist GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 receptor agonists show promise
Description
Sequence: Y-Aib-E-G-T-F-T-S-D-Y-S-I-Aib-L-D-K-I-A-Q-Aib-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes
Individual results may vary
This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database
It is not approved yet, but the data is starting to demand attention
